SEARCH

SEARCH BY CITATION

References

  • 1
    Kanis JA 2002 Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359:19291936.
  • 2
    National Osteoporosis Foundation 1988 Osteoporosis: Review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis. Osteoporos Int 8(Suppl 4):S1S88.
  • 3
    Kanis JA, Delmas P, Burckhardt P, Cooper C, Torgerson D, for the European Foundation for Osteoporosis and Bone Disease 1997 Guidelines for diagnosis and management of osteoporosis. Osteoporos Int 7:390406.
  • 4
    Kanis JA, Johnell O, Oden A, De Laet C, Jonsson B, Dawson A 2002 Ten-year risk of osteoporotic fracture and the effect of risk factors on screening strategies. Bone 30:251258.
  • 5
    Delmas PD 2002 Treatment of postmenopausal osteoporosis. Lancet 359:20182026.
  • 6
    Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR 1999 Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282:637645.
  • 7
    Garnero P, Delmas PD 1993 Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease. J Clin Endocrinol Metab 77:10461053.
  • 8
    Garnero P, Grimaux M, Demiaux B, Preaudat C, Seguin P, Delmas PD 1992 Measurement of serum osteocalcin with a human-specific two-site immunoradiometric assay. J Bone Miner Res 7:13891398.
  • 9
    Bonde M, Qvist P, Fledelius C, Riis BJ, Christiansen C 1994 Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin Chem 40:20222025.
  • 10
    Morris JC, Heyman A, Mohs RC, Hughes JP, van Belle G, Fillenbaum G, Mellits ED, Clark C 1989 The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology 39:11591165.
  • 11
    Yaffe K, Krueger K, Sarkar S, Grady D, Barrett-Connor E, Cox DA, Nickelsen T, Multiple Outcomes of Raloxifene Evaluation Investigators 2001 Cognitive function in postmenopausal women treated with raloxifene. N Engl J Med 344:12071213.
  • 12
    Katzman R, Brown T, Fuld P, Peck A, Schechter R, Schimmel H 1983 Validation of a short Orientation-Memory-Concentration Test of cognitive impairment. Am J Psychiatry 140:734739.
  • 13
    Reitan RM 1958 Validity of the Trail Making Test as an indicator of organic brain damage. Percept Mot Skills 8:271276.
  • 14
    Isaacs B, Kennie AT 1973 The Set test as an aid to the detection of dementia in old people. Br J Psychiatry 123:467470.
  • 15
    Buchner DM, Hornbrook MC, Kutner NG, Tinetti ME, Ory MG, Mulrow CD, Schechtman KB, Gerety MB, Fiatarone MA, Wolf SL 1993 Development of the common data base for the FICSIT trials. J Am Geriatr Soc 41:297308.
  • 16
    Lu Y, Mathur AK, Blunt BA, Gluer CC, Will AS, Fuerst TP, Jergas MD, Andriano KN, Cummings SR, Genant HK 1996 Dual X-ray absorptiometry quality control: Comparison of visual examination and process-control charts. J Bone Miner Res 11:626637.
  • 17
    Genant HK, Jergas M, Palermo L, Nevitt M, Valentin RS, Black D, Cummings SR 1996 Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis The Study of Osteoporotic Fractures Research Group. J Bone Miner Res 11:984996.
  • 18
    Hosmer DW, Lemeshow S 2000 Applied Logistic Regression. John Wiley & Sons, New York, NY, USA, pp. 144167.
  • 19
    Roy DK, O'Neill TW, Finn JD, Lunt M, Silman AJ, Felsenberg D, Armbrecht G, Banzer D, Benevolenskaya LI, Bhalla A, Armas Bruges J, Cannata JB, Cooper C, Dequeker J, Diaz MN, Eastell R, Yershova OB, Felsch B, Gowin W, Havelka S, Hoszowski K, Ismail AA, Jajic I, Janott I, Johnell O, Kanis JA, Kragl G, Vaz Lopez A, Lorenc R, Lyritis G, Masaryk P, Matthis C, Miazgowski T, Gennari C, Pols HA, Poor G, Raspe HH, Reid DM, Reisinger W, Scheidt-Nave C, Stepan JJ, Todd CJ, Weber K, Woolf AD, Reeve J, for the European Prospective Osteoporosis Study 2003 Determinants of incident vertebral fracture in men and women: Results from the European Prospective Osteoporosis Study (EPOS). Osteoporos Int 14:1926.
  • 20
    Melton LJ III 1997 Epidemiology of spinal osteoporosis. Spine 22(24 Suppl):2S11S.
  • 21
    Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD 2000 Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: The OFELY study. J Bone Miner Res 15:15261536.
  • 22
    Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J 2000 The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int 11(Suppl 6):S2S17.
  • 23
    Chapurlat RD, Ewing SK, Bauer DC, Cummings SR 2001 Influence of smoking on the antiosteoporotic efficacy of raloxifene. J Clin Endocrinol Metab 86:41784182.
  • 24
    Cummings SR, Duong T, Kenyon E, Cauley JA, Whitehead M, Krueger KA 2002 Serum estradiol level and risk of breast cancer during treatment with raloxifene. JAMA 287:216220.
  • 25
    Johnell O, Kanis JA, Sakar S, Wu W, De Laet C, Oden A, Pavo I 2001 Relationship between age and prior use of HRT on vertebral fracture risk reduction with raloxifene in postmenopausal women: Results from the MORE trial. J Bone Miner Res 16:S1;S414.
  • 26
    Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD 2002 Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 17:110.
  • 27
    Bjarnason NH, Sarkar S, Duong T, Mitlak B, Delmas PD, Christiansen C 2001 Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos Int 12:922930.
  • 28
    Espallargues M, Sampietro-Colom L, Estrada MD, Sola M, del Rio L, Setoain J, Granados A 2001 Identifying bone-mass-related risk factors for fracture to guide bone densitometry measurements: A systematic review of the literature. Osteoporos Int 12:811822.
  • 29
    Kado DM, Browner WS, Palermo L, Nevitt MC, Genant HK, Cummings SR 1999 Vertebral fractures and mortality in older women: A prospective study. Study of Osteoporotic Fractures Research Group. Arch Intern Med 159:12151220.
  • 30
    Ismail AA, Cooper C, Felsenberg D, Varlow J, Kanis JA, Silman AJ, O'Neill TW 1999 Number and type of vertebral deformities: Epidemiological characteristics and relation to back pain and height loss. European Vertebral Osteoporosis Study Group. Osteoporos Int 9:206213.
  • 31
    Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA 1999 Mortality after all major types of osteoporotic fracture in men and women: An observational study. Lancet 353:878882.
  • 32
    Cummings SR, Melton LJ 2002 Epidemiology and outcomes of osteoporotic fractures. Lancet 359:17611767.
  • 33
    Marshall D, Johnell O, Wedel H 1996 Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312:12541259.
  • 34
    Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA III, Berger M 2000 Patients with prior fractures have an increased risk of future fractures: A summary of the literature and statistical synthesis. J Bone Miner Res 15:721739.
  • 35
    Janott J, Hallner D, Pfeiffer A 1996 Risk factors of osteoporosis: Results of EVOS in Germany. Scand J Rheumatol 25(Suppl 103):123.
  • 36
    Wasnich RD, Ross PD, MacLean CJ 1987 The relative strengths of osteoporotic risk factors in a prospective study of postmenopausal osteoporosis. In: Christiansen C, Johansen JS, Riis BJ (eds.) Osteoporosis. Proceedings of the International Symposium on Osteoporosis. Osteopress, Copenhagen, Denmark, pp. 394395.
  • 37
    O'Neill TW, Silman AJ, Diaz Naves M, Cooper C, Kanis J, Felsenberg D 1997 Influence of hormonal and reproductive factors on the risk of vertebral deformity in European women. Osteoporos Int 7:7278.